Results 121 to 130 of about 5,265 (145)

Daclatasvir + sofosbuvir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source

Sofosbuvir Adsorption Onto Activated Carbon Derived From Argan Shell Residue: Optimization, Kinetic, Thermodynamic and Theoretical Approaches

Journal of Molecular Liquids, 2022
Ismail Warad, G Kaichouh
exaly  

Sofosbuvir: First Global Approval

Drugs, 2014
Gillian M Keating
exaly  

Sofosbuvir With Pegylated Interferon Alfa-2a and Ribavirin for Treatment-Naive Patients With Hepatitis C Genotype-1 Infection (ATOMIC): An Open-Label, Randomised, Multicentre Phase 2 Trial

Lancet, The, 2013
Mitchell N Davis, Eric Lawitz, Nezam Afdhal   +2 more
exaly  

Evolution of eGFR in Chronic HCV Patients Receiving Sofosbuvir-Based or Sofosbuvir-Free Direct-Acting Antivirals

Journal of Hepatology, 2020
Ding-Shinn Chen, Hsing Yu Chen, Chen Pei-jer   +2 more
exaly  

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Clinical Infectious Diseases, 2014
Eric Lawitz, Ross Martin, Edward Gane
exaly  

Prices of sofosbuvir and ledipasvir/sofosbuvir unaffordable

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Simeprevir Plus Sofosbuvir, With or Without Ribavirin, to Treat Chronic Infection With Hepatitis C Virus Genotype 1 in Non-Responders to Pegylated Interferon and Ribavirin and Treatment-Naive Patients: The COSMOS Randomised Study

Lancet, The, 2014
Paul J Pockros, Mark Sulkowski
exaly  

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Gastroenterology, 2016
Lauren A Beste, Michael F Chang, Feng Su
exaly  

Sofosbuvir

Reactions Weekly, 2015
openaire   +2 more sources